PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. - Wikidata - wikimedia - TriplyDB

PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans.

PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans.

http://www.wikidata.org/entity/Q35000567

about

Integrated physiology and systems biology of PPARα PPARα gene polymorphisms modulate the association between physical activity and cardiometabolic risk.PPARs in the Renal Regulation of Systemic Blood Pressure Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.PPARalpha in atherosclerosis and inflammation.Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction.Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin s Relationship Between Glucocorticoids and Insulin Resistance in Healthy Individuals.PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension An afferent vagal nerve pathway links hepatic PPARalpha activation to glucocorticoid-induced insulin resistance and hypertension.Effect of bezafibrate on office, home and ambulatory blood pressure in hypertensive patients with dyslipidemia.Interaction of low dose of fish oil and glucocorticoids on insulin sensitivity and lipolysis in healthy humans: A randomized controlled study.

P2860

Q24564130-CF42407C-D1C7-4957-AA12-F85EDE6CE6C1 Q33728875-F87AF115-43C3-4EFB-9DC6-F8247AC69F04 Q33960908-751B13EC-F804-4D3D-A242-2E9B1E1594A3 Q34501780-B09F579B-C855-4215-AD52-0F4B80BFCF67 Q36154953-A9426904-8F62-4061-8EAF-1AE27F6F0791 Q36807491-D0057FFA-A8C4-40DD-80E4-F2C25BE322AE Q36933753-9CD490C4-1EB6-4DFD-B8D7-DF61DC5A7221 Q36979704-9977DE4A-B941-48E9-BF1A-DF366E617A53 Q37021004-E03D7B9B-ED9A-435E-B3EB-A243D58592FE Q37183113-ACF76C2D-0668-4F90-9DE5-F15DFEA29C57 Q37238488-A91AAB26-184B-4CA6-A62A-9649322653F9 Q42738598-7ED78AEA-E910-47D6-9253-048C349AF65B Q46094863-8BE64DD5-5578-49DE-A1FC-80F54615E2D1 Q53799709-30DE0E57-4704-4323-949A-CD73CEE9D473

P2860

PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans.

http://www.wikidata.org/entity/Q35000567

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

PPARalpha activation elevates ...... insulin resistance in humans.

@ast

PPARalpha activation elevates ...... insulin resistance in humans.

@en

type

label

PPARalpha activation elevates ...... insulin resistance in humans.

@ast

PPARalpha activation elevates ...... insulin resistance in humans.

@en

prefLabel

PPARalpha activation elevates ...... insulin resistance in humans.

@ast

PPARalpha activation elevates ...... insulin resistance in humans.

@en

P1433

Q35000567-EAB9B73A-B9B4-433F-AF84-0EB4E2393049

P1476

Q35000567-2549B6F3-B452-4078-8B01-441D603AED23

P2093

Q35000567-6828C189-0973-4418-86A7-D5F10E392883

Q35000567-6997FEED-8158-47F0-940F-48189F528956

Q35000567-6CB34669-F658-4595-8AA7-4120F01E74D8

Q35000567-84588ABF-1FA0-49E5-93F7-614D2BAFE090

Q35000567-8D0B1D9E-7263-4A40-B30C-9316AB86E526

Q35000567-CA28DAC1-7B54-4DB8-9858-D469AC3E64AA

P2860

Q35000567-12E9D2F6-1FFA-4271-9F00-D93E6D9B48CB

Q35000567-17DD0127-EA69-4C80-92B4-E2BB40D8DB92

Q35000567-1DA1E674-4DCE-4B0A-A4FA-0D18398CAA00

Q35000567-37F14A43-910C-4845-BBFF-51CC98FB27D4

Q35000567-3D18B03E-040C-4399-AF7A-3FDF9DA921BD

Q35000567-63BC252D-023B-4D0F-90E6-850DCA323D32

Q35000567-6876C196-F9A9-48F2-BD70-9780C32FA354

Q35000567-6B4B8F34-6A4D-40C5-9B84-05DF769390F6

Q35000567-6B745F2C-6DF1-4982-8ECE-7E5D51707478

Q35000567-6BA575C3-1924-4F9C-A40C-F6E67D3C0A01

P304

Q35000567-FC4B2D6A-C3F4-4FB7-B729-937082954FEE

P31

Q35000567-06F038FA-5B1A-4417-87DD-99CD71893098

P356

Q35000567-1D2335EC-E58B-4441-A8E3-D7E4350A013C

P433

Q35000567-21E140DD-DEFD-474B-BBEF-3A8C721E8329

P478

Q35000567-3401CDC3-8CCC-478F-8A4F-CB0E131FE72F

P50

Q35000567-BDF26C09-0DD2-424F-9521-7822E85DAF6A

Q35000567-D99C7205-D43D-4B92-90F5-E024616D21A8

P577

Q35000567-AE4CBA8B-524F-4E65-96CD-8112A92FE962

P5875

Q35000567-F6415DCA-44F5-4DE2-8294-930B021DC945

P698

Q35000567-9A01CBFD-4265-4279-A877-AFE27BF4400A

P932

Q35000567-1ABFBB2A-17E0-4B4C-86BF-F34BBE89AF5A

P356

AJPENDO.00230.2006

P1433

American Journal of Physiology - Endocrinology and Metabolism

P1476

PPARalpha activation elevates ...... insulin resistance in humans.

@en

P2093

Carlos Bernal-Mizrachi

http://www.w3.org/2001/XMLSchema#string

Michael A DeRosa

http://www.w3.org/2001/XMLSchema#string

Nicholas Laffely

http://www.w3.org/2001/XMLSchema#string

Philip E Cryer

http://www.w3.org/2001/XMLSchema#string

Savitha Subramanian

http://www.w3.org/2001/XMLSchema#string

William T Cade

http://www.w3.org/2001/XMLSchema#string

P2860

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor ex

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Cushing, cortisol, and cardiovascular disease.

P304

E1365-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPENDO.00230.2006

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

291

http://www.w3.org/2001/XMLSchema#string

P50

Kevin Yarasheski

Clay F. Semenkovich

P577

2006-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6918551

http://www.w3.org/2001/XMLSchema#string

P698

16868225

http://www.w3.org/2001/XMLSchema#string

P932

4303180

http://www.w3.org/2001/XMLSchema#string